Drug Trial Radar · NCT06859775
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Apr 25, 2025
Primary completion
Oct 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.
Conditions
- Recurrent or Metastatic Cervical Cancer
Interventions
SHR-A1811Drug
SHR-A1811 injection.
Adebelimab injectionDrug
Adebelimab injection.
Bevacizumab injectionDrug
Bevacizumab injection.
SHR-8068Drug
SHR-8068 injection.
Cisplatin injectionDrug
Cisplatin injection.
Carboplatin injectionDrug
Carboplatin injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Grade≥3 drug-related adverse events (TRAEs).Time frame: Up to 3 years.
- Grade≥3 drug-related serious adverse events (TRAEs).Time frame: Up to 3 years.
- Objective response rate (ORR).Time frame: Up to 3 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.